艾司西酞普兰联合喹硫平治疗广泛性焦虑障碍的疗效观察

何俊; 宋明芬; 施剑飞; 陶云海; 高甜; 申变红; 乔蓉<sup>*</sup>

引用本文:	何俊,宋明芬,施剑飞,陶云海,高甜,申变红,乔蓉.艾司西酞普兰联合喹硫平治疗广泛性焦虑障碍的疗效观察[J].中国现代应用药学,2014,31(11):1407-1411.
	HE Jun,SONG Mingfen,SHI Jianfei,TAO Yunhai,GAO Tian,SHEN Bianhong,QIAO Rong.Randomized Controlled Trial of Quetiapine Combined with Escitalopram in the Treatment of General Anxiety Disorder[J].Chin J Mod Appl Pharm(中国现代应用药学),2014,31(11):1407-1411.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 2971次下载 1698次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
艾司西酞普兰联合喹硫平治疗广泛性焦虑障碍的疗效观察
何俊¹, 宋明芬², 施剑飞³, 陶云海³, 高甜¹, 申变红³, 乔蓉³
1.杭州市第七人民医院药剂科，杭州 310013;2.杭州市第七人民医院分子生物实验室，杭州 310013;3.杭州市第七人民医院精神科，杭州 310013

摘要:

目的评价艾司西酞普兰联合喹硫平治疗广泛性焦虑障碍(GAD)的疗效、安全性和可行性。方法采用随机、双盲、平行对照研究。60例患者随机分为艾司西酞普兰喹硫平组(研究组)和艾司西酞普兰(对照组)，每组30例，疗程为8周。在治疗前和第1，2，4，6，8周末进行汉密尔顿焦虑量表(HAMA)及临床疗效总评量表的病情严重度(CGI-SI)等评定疗效。用副反应量表(TESS)、心电图(ECG)检查、实验室检查评定安全性。结果与治疗前比较，2组在第8周末HAMA、CGI-SI评分均显著下降(P<0.05)；第1周末，研究组显著下降(P<0.05)，对照组下降无统计学差异。组间HAMA比较有统计学意义(P<0.05)。CGI-SI在第1，2，4周末比较有统计学意义(P<0.05)。研究组和对照组治疗有效率分别为86.7％和70％，差异有统计学意义(P<0.05)；不良反应发生率分别为20.0％和23.3％，差异无统计学意义。结论喹硫平联用艾司西酞普兰治疗广泛性焦虑障碍疗效确切、起效快、不良反应轻。

关键词: 艾司西酞普兰广泛性焦虑障碍喹硫平

DOI：

分类号:

基金项目:杭州市科技发展计划项目(20130733Q26，20130733Q27)

Randomized Controlled Trial of Quetiapine Combined with Escitalopram in the Treatment of General Anxiety Disorder

HE Jun¹, SONG Mingfen², SHI Jianfei³, TAO Yunhai³, GAO Tian¹, SHEN Bianhong³, QIAO Rong³

1.The Seventh People’s Hospital of Hangzhou, Department of Pharmacy, Hangzhou 310013, China;2.The Seventh People’s Hospital of Hangzhou, Laboratory of Molecular Biology, Hangzhou 310013, China;3.The Seventh People’s Hospital of Hangzhou, Department of Psychopathy, Hangzhou 310013, China

Abstract:

OBJECTIVE To explore the efficacy and safety of quetiapine combined with escitalopram in the treatment of general anxiety disorder. METHODS In the 8-week, randomized, double-blind, and parallel controlled clinical trial, sixty patients were randomly divided into quetiapine and escitalopram(study) group and escitalopram(control) group, 30 for each group. All the patients were assessed with HAMA and CGI-SI before treatment and after 1, 2, 4, 6 and 8 weeks of treatment. Safety measures included adverse reactions, laboratory examination and electrocardiogram were observed. RESULTS Compared with before treatment, HAMA and CGI-SI decreased significantly in study group and control group. In the end first week, compared with before treatment, HAMA and CGI-SI decreased significantly in study group, while it was not significantly in control group. HAMA was significantly different between control group and study group of HAMA in the end of each week. CGI-SI was significantly different between control group and study group in the end of 1st, 2nd and 4th week. Efficiency was 86.7% and 70% in study group and control group, there was significant difference(P<0.05). Incidence of adverse reactions in control group and study group was 20.0% and 23.3%, respectively, there was no significant difference. CONCLUSION Quetiapine combined with escitalopram has a more rapid effect and safety on controlling general anxiety disorder than escitalopram.

Key words: escitalopram general anxiety disorder quetiapine